RERB Program (Oncology)

About CCRP Therapeutics

CCRP Therapeutics is a Munich-based, preclinical-stage biotech developing first-in-class small molecule inhibitors of the renin/prorenin receptor (RERBs). Originating from the prestigious Charité hospital, the company is pursuing a dual therapeutic strategy targeting multiple solid tumors and chronic end-organ damage, representing a novel approach in both oncology and cardiometabolic diseases. As a private, early-stage spin-off, its success hinges on validating its unique mechanism and advancing its lead candidates into clinical trials.

Therapeutic Areas